Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Briumvi is a prescription CD20-directed monoclonal antibody containing ublituximab-xiiy. It is approved for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Briumvi is given by intravenous infusion after screening for hepatitis B, immunoglobulin levels, and liver tests.
read more about briumvi ...Ublituximab-xiiy binds CD20, a cell-surface antigen found on pre-B and mature B lymphocytes. After binding, it causes B-cell lysis through antibody-dependent cellular cytolysis and complement-dependent cytolysis. The precise mechanism behind its therapeutic effects in multiple sclerosis is unknown, but reduction of circulating B cells is part of its pharmacologic activity.
Briumvi is approved for relapsing forms of multiple sclerosis in adults. The listed forms are clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive disease. Safety and efficacy in pediatric patients have not been established under current U.S. prescribing information.
The first Briumvi infusion is 150 mg. A 450 mg second infusion is given two weeks later. The next 450 mg infusion is given 24 weeks after the first infusion, followed by 450 mg every 24 weeks. A corticosteroid and an antihistamine are given before each infusion to reduce infusion reactions.
Serious concerns include infusion reactions, severe infections, hepatitis B reactivation, progressive multifocal leukoencephalopathy, reduced immunoglobulin levels, liver injury, and potential fetal harm. Active hepatitis B infection and a history of life-threatening Briumvi infusion reaction are contraindications. Blood tests and infection screening are completed before treatment, with continued monitoring during therapy.
Briumvi treats clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
After the first two infusions, 450 mg is given 24 weeks after the first infusion and every 24 weeks afterward.
Anti-CD20 therapy is linked to hepatitis B reactivation, which has resulted in severe liver complications with this drug class.
Yes. A corticosteroid and an antihistamine are given before each infusion to reduce the frequency and severity of infusion reactions.
BRIUMVI (ublituximab-xiiy) Medication Guide. https://briumvi.com/wp-content/uploads/2022/12/Med-Guide.pdf. Date Accessed September 17, 2026.
BRIUMVI (ublituximab-xiiy) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761238s022s025lbl.pdf. Date Accessed September 17, 2026.
Drug Trials Snapshots: BRIUMVI. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-briumvi. Date Accessed September 17, 2026.
Supplement Approval - BRIUMVI (ublituximab-xiiy) Injection. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761238Orig1s026ltr.pdf. Date Accessed September 17, 2026.
Ublituximab-xiiy Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623008.html. Date Accessed September 17, 2026.